ClinicalTrials.gg

Program

ALXN1920

A development code.

Its studies are mostly in Glomerulonephritis, Membranous, led by AstraZeneca.

Furthest: phase 2, since Aug 28, 20252 company-led studies, 1 open or runningNext primary completion: Jul 2, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca21 open or runningphase 2since Aug 28, 2025Feb 21, 2023Jul 2, 2027phase 2 · NCT07157787
  • Named in AstraZeneca’s own pipeline as ALXN1920, phase 2, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 21, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT05751642 · 48 enrolled · New Zealand
  2. Aug 28, 2025Phase 2 study in Primary Membranous NephropathyNCT07157787 · 30 planned · United States, Argentina, Australia and more

Ahead

  1. Jul 2, 2027Primary completion: phase 2 study in Primary Membranous NephropathyNCT07157787

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07157787Primary Membranous Nephropathy · United States, Argentina, Australia and more2RecruitingJul 2, 202730
NCT05751642Healthy Participants · New Zealand1CompletedDec 4, 202348

How it is read

Names in the registry

  • “ALXN1920”, 4 entries

Codes read as this program: ALXN1920.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.